Aaron J. Bernstein, Renske Keeman, Amber Hurson, Fiona M. Blows, Manjeet K. Bolla, Jodi L. Miller, Roger Milne, Hugo Horlings, Alexandra J. van den Broek, Clara Bodelon, James Hodge, Alpa Patel, Lauren R. Teras, Federico Canzian, Rudolf Kaaks, Hermann Brenner, Ben Schoettker, Sabine Behrens, Jenny Chang-Claude, Tabea Maurer, Nadia Obi, Fergus Couch, H. Raza Ali, Carlos Caldas, Irene Andrulis, Gord Glendon, Anna Marie Mulligan, Wilma Mesker, Agnes Jager, Annette Heemskerk-Gerritsen, Peter Devilee, Scott M. Lawrence, Jolanta Lissowska, Karun Mutreja, Thomas Ahearn, Stephen Chanock, Maire A. Duggan, Diana Eccles, J. Louise Jones, Will Tapper, Antoinette Hollestelle, Maartje Hooning, John Martens, Carolien H.M. van Deurzen, Angela Cox, Simon S. Cross, Mikael Hartman, Jingmei Li, Thomas C. Putti, Ute Hamann, Ania Jakubowska, Nicki Camp, Melissa H. Cessna, Amy Berrington de Gonzalez, Katarzyna Bialkowska, Jacek Gronwald, Jan Lubi_ski, Siddhartha Yadav, Pietro Lio, Doug F. Easton, Mustapha Abubakar, Montse Garcia-Closas, Paul D.P. Pharoah, Marjanka K. Schmidt
{"title":"Spatially-resolved tumour infiltrating immune cells and prognosis in breast cancer","authors":"Aaron J. Bernstein, Renske Keeman, Amber Hurson, Fiona M. Blows, Manjeet K. Bolla, Jodi L. Miller, Roger Milne, Hugo Horlings, Alexandra J. van den Broek, Clara Bodelon, James Hodge, Alpa Patel, Lauren R. Teras, Federico Canzian, Rudolf Kaaks, Hermann Brenner, Ben Schoettker, Sabine Behrens, Jenny Chang-Claude, Tabea Maurer, Nadia Obi, Fergus Couch, H. Raza Ali, Carlos Caldas, Irene Andrulis, Gord Glendon, Anna Marie Mulligan, Wilma Mesker, Agnes Jager, Annette Heemskerk-Gerritsen, Peter Devilee, Scott M. Lawrence, Jolanta Lissowska, Karun Mutreja, Thomas Ahearn, Stephen Chanock, Maire A. Duggan, Diana Eccles, J. Louise Jones, Will Tapper, Antoinette Hollestelle, Maartje Hooning, John Martens, Carolien H.M. van Deurzen, Angela Cox, Simon S. Cross, Mikael Hartman, Jingmei Li, Thomas C. Putti, Ute Hamann, Ania Jakubowska, Nicki Camp, Melissa H. Cessna, Amy Berrington de Gonzalez, Katarzyna Bialkowska, Jacek Gronwald, Jan Lubi_ski, Siddhartha Yadav, Pietro Lio, Doug F. Easton, Mustapha Abubakar, Montse Garcia-Closas, Paul D.P. Pharoah, Marjanka K. Schmidt","doi":"10.1101/2024.07.22.24310819","DOIUrl":null,"url":null,"abstract":"Background\nThe immune response in breast tumors has an important role in prognosis, but the role of spatial localization of immune cells and of interaction between subtypes is not well characterized. We evaluated the association between spatially resolved tissue infiltrating immune cells (TIICs) and breast cancer specific survival (BCSS) in a large multicenter study.\nPatients and methods\nTissue microarrays with tumor cores from 17,265 breast cancer patients of European descent were stained for CD8, FOXP3, CD20, and CD163. We developed a machine learning based tissue segmentation and immune cell detection algorithm using Halo to score each image for the percentage of marker positive cells by compartment (overall, stroma, or tumor). We assessed the association between log transformed TIIC scores and BCSS using Cox regression. Results\nTotal CD8+ and CD20+ TIICs (stromal and intra-tumoral) were associated with better BCSS in women with ER-negative (HR per standard deviation = 0.91 [95% CI 0.85 - 0.98] and 0.89 [0.84 - 0.94] respectively) and ER-positive disease (HR = 0.92 [95% CI 0.87 - 0.98] and 0.93 [0.86 - 0.99] respectively) in multi-marker models. In contrast, CD163+ macrophages were associated with better BCSS in ER-negative disease (0.94 [0.87 - 1.00]) and a poorer BCSS in ER-positive disease 1.04 [0.99 - 1.10]. There was no association between FOXP3 and BCSS. The observed associations tended to be stronger for intra-tumoral than stromal compartments for all markers. However, the TIIC markers account for only 7.6 percent of the variation in BCSS explained by the multi-marker fully-adjusted model for ER-negative cases and 3.0 percent for ER-positive cases.\nConclusions\nThe presence of intra-tumoral and stromal TIICs is associated with better BCSS in both ER-negative and ER-positive breast cancer. This may have implications for the use of immunotherapy. However, the addition of TIICs to existing prognostic models would only result in a small improvement in model performance.","PeriodicalId":501437,"journal":{"name":"medRxiv - Oncology","volume":"53 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.07.22.24310819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The immune response in breast tumors has an important role in prognosis, but the role of spatial localization of immune cells and of interaction between subtypes is not well characterized. We evaluated the association between spatially resolved tissue infiltrating immune cells (TIICs) and breast cancer specific survival (BCSS) in a large multicenter study.
Patients and methods
Tissue microarrays with tumor cores from 17,265 breast cancer patients of European descent were stained for CD8, FOXP3, CD20, and CD163. We developed a machine learning based tissue segmentation and immune cell detection algorithm using Halo to score each image for the percentage of marker positive cells by compartment (overall, stroma, or tumor). We assessed the association between log transformed TIIC scores and BCSS using Cox regression. Results
Total CD8+ and CD20+ TIICs (stromal and intra-tumoral) were associated with better BCSS in women with ER-negative (HR per standard deviation = 0.91 [95% CI 0.85 - 0.98] and 0.89 [0.84 - 0.94] respectively) and ER-positive disease (HR = 0.92 [95% CI 0.87 - 0.98] and 0.93 [0.86 - 0.99] respectively) in multi-marker models. In contrast, CD163+ macrophages were associated with better BCSS in ER-negative disease (0.94 [0.87 - 1.00]) and a poorer BCSS in ER-positive disease 1.04 [0.99 - 1.10]. There was no association between FOXP3 and BCSS. The observed associations tended to be stronger for intra-tumoral than stromal compartments for all markers. However, the TIIC markers account for only 7.6 percent of the variation in BCSS explained by the multi-marker fully-adjusted model for ER-negative cases and 3.0 percent for ER-positive cases.
Conclusions
The presence of intra-tumoral and stromal TIICs is associated with better BCSS in both ER-negative and ER-positive breast cancer. This may have implications for the use of immunotherapy. However, the addition of TIICs to existing prognostic models would only result in a small improvement in model performance.